Immunomodulatory therapy of human type 1 diabetes: Lessons from the mouse

Journal of Clinical Investigation

Volumn 108, Issue 1, 2001, Pages 31-33

  Palmer, J P ^a  

^a Veterans Puget Sound Health Care System   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOMODULATING AGENT;

DRUG RESEARCH; HUMAN; IMMUNOMODULATION; INSULIN DEPENDENT DIABETES MELLITUS; MOUSE; NONHUMAN; NOTE; PATHOGENESIS; PRIORITY JOURNAL; REMISSION;

ADOPTIVE TRANSFER; ADULT; ANIMALS; AUTOANTIBODIES; AUTOIMMUNE DISEASES; CELL TRANSPLANTATION; CLINICAL TRIALS; CYCLOSPORINE; DIABETES MELLITUS, TYPE 1; DISEASE MODELS, ANIMAL; FEMALE; FREUND'S ADJUVANT; GLUTAMATE DECARBOXYLASE; GRAFT ENHANCEMENT, IMMUNOLOGIC; GRAFT SURVIVAL; H-2 ANTIGENS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INSULIN; ISLETS OF LANGERHANS; ISLETS OF LANGERHANS TRANSPLANTATION; MALE; MICE; MICE, INBRED C57BL; MICE, INBRED NOD; MICE, KNOCKOUT; MULTICENTER STUDIES; NEPHRECTOMY; NIACINAMIDE; PANCREATECTOMY; T-LYMPHOCYTES;

EID: 0034932610     PISSN: 00219738     EISSN: None     Source Type: Journal    
DOI: 10.1172/JCI200113445     Document Type: Note

References (21)

1. Reversal of established autoimmune diabetes by restoration of endogenous β cell function
2. Clinical and genetic characteristics off type 2 diabetes with and without GAD antibodies
3. Type 1 1/2 diabetes: Myth or reality?
4. CD3 antibody-induced dominant self tolerance in overtly diabetic NOD mice
5. Reversal of β-cell suppression in vitro in pancreatic islets isolated from nonobese diabetic mice during the phase preceding insulin-dependent diabetes mellitus
6. Role of infiltrating T-cells for impaired glucose metabolism in pancreatic islets isolated from non-obese mice
7. Lessons learned from use of cyclosporine for insulin-dependent diabetes mellitus: The case for immunotherapy for insulin-dependent diabetics having residual insulin secretion
8. Effects of age, duration and treatment of insulin-dependent diabetes mellitus on residual β-cell function: Observations during eligibility testing for the Diabetes Control and Complications Trial (DCCT)
9. Correlations of in vivo beta cell function tests with beta cell mass and pancreatic insulin content in streptozocin-administered baboons
10. The functional state of the beta cell affects expression of both forms of glutamic acid decarboxylase
11. The functional state of the beta cell modulates IL-1 and TNF induced cytotoxicity
12. Reduction of diabetes incidence of BB Wistar rats by early prophylactic insulin treatment of diabetes-prone animals
13. Immunological and metabolic effects of prophylactic insulin therapy in the NOD-scid/scid adoptive transfer model of IDDM
14. Diazoxide treatment at onset preserves residual insulin secretion in adults with autoimmune diabetes
15. Effect of intensive therapy on residual β-cell function in patients with type 1 diabetes in the diabetes control and complications trial: A randomized, controlled trial
16. The NOD mouse model of type 1 diabetes: As good as ir gets?
17. Insulin prophylaxis in individuals at high risk of type 1 diabetes
18. UKPDS 25: Autoantibodies to islet-cell cytoplasm and glutamic acid decarboxylase for prediction of insulin requirement in type 2 diabetes
19. Small doses of subcutaneous-insulin as a strategy for preventing slowly progressive β-cell failure in islet cell antibody-positive patients with clinical features of NIDDM
20. Multicenter prevention trial of slowly progressive IDDM with small dose of insulin (the Tokyo Study)
21. Islet transplantation in seven patients with type 1 diabetes mellitus using a glucocorticoid-free immunosuppressive regimen